GLP-1 gene delivery for the treatment of type 2 diabetes

Molecular Therapy

Volumn 7, Issue 4, 2003, Pages 478-483

  Oh, Seungjoon ^a   Lee, Minhyung ^b   Ko, Kyung Soo ^c   Choi, Suna ^d   Kim, Sung Wan ^d  

^a Kyung Hee University Hospital   (South Korea)

^b Inha University School of Medicine   (South Korea)

^c Inje University   (South Korea)

^d UNIVERSITY OF UTAH   (United States)

Author keywords

Diabetes mellitus; Gene therapy; GLP 1; Type 2

Indexed keywords

BETA ACTIN; COMPLEMENTARY DNA; FURIN; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; MESSENGER RNA; PLASMID VECTOR; POLYETHYLENEIMINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ISOLATION; COCULTURE; CONTROLLED STUDY; DNA CLEAVAGE; DNA MODIFICATION; GENE DOSAGE; GENE EXPRESSION; GENETIC CODE; GENETIC TRANSFECTION; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; HYPERGLYCEMIA; IN VITRO STUDY; IN VIVO STUDY; INSULIN RELEASE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PANCREAS ISLET CELL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROVOCATION TEST; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; START CODON;

ANIMALIA; GALLUS GALLUS;

EID: 0038027366     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1525-0016(03)00036-4     Document Type: Article

References (21)

1. DeFronzo, R. A., Bonadonna, R. C., and Ferrannini, B. E. (1995). Pathogenesis of NIDDM: a precarious balance between insulin action and insulin secretion. In International Textbook of Diabetes Mellitus (K. G. M. M. Alberti, P. Zimmet, R. A. DeFronzo, and H. Keen, Eds.), pp. 569-633. Wiley, Chichester, UK.
2. Unger, R. H., and Eisentraut, A. M. (1969). Entero-insular axis. Arch. Intern. Med. 123: 261-266.
3. Holst, J. J. (1994). Glucagonlike peptide 1: a newly discovered gastrointestinal hormone. Gastroenterology 107: 1848-1855.
4. Nauck, M. A., et al. (1993). Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J. Clin. Invest. 91: 301-307.
5. Perfetti, R., and Merkel, P. (2000). Glucagon-like peptide-1: a major regulator of pancreatic beta-cell function. Eur. J. Endocrinol. 143: 717-725.
6. Fehmann, H. C., Goke, R., and Goke, B. (1995). Cell and molecular biology of the incretin hormones glucagon-like peptide-1 and glucose-dependent insulin releasing polypeptide. Endocr. Rev. 16: 390-410.
7. Nauck, M. A., Sauerwald, A., Ritzel, R., Holst, J. J., and Schmiegel, W. (1998). Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure. Diabetes Care 21: 1925-1931.
8. Rachman, J., Barrow, B. A., Levy, J. C., and Turner, R. C. (1997). Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM. Diabetologia 40: 205-211.
9. Szayna, M., et al. (2000). Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinology 141: 1936-1941.
10. Hargrove, D. M., Nardone, N. A., Persson, L. M., Parker, J. C., and Stevenson, R. W. (1995). Glucose-dependent action of glucagon-like peptide-1 (7-37) in vivo during short- or long-term administration. Metabolism 44: 1231-1237.
11. Shen, H. Q., Roth, M. D., and Peterson, R. G. (1998). The effect of glucose and glucagon-like peptide-1 stimulation on insulin release in the perfused pancreas in a non-insulin-dependent diabetes mellitus animal model. Metabolism 47: 1042-1047.
12. Ritzel, R., et al. (2001). Glucagon-like peptide 1 increases secretory burst mass of pulsatile insulin secretion in patients with type 2 diabetes and impaired glucose tolerance. Diabetes 50: 776-784.
13. Vilsboll, T., Krarup, T., Deacon, C. F., Madsbad, S., and Holst, J. J. (2001). Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 50: 609-613.
14. Vilsboll, T., Krarup, T., Madsbad, S., and Holst, J. J. (2001). No reactive hypoglycaemia in Type 2 diabetic patients after subcutaneous administration of GLP-1 and intravenous glucose. Diabetes Med. 18: 144-149.
15. Hui, H., Yu, R., Bousquet, C., and Perfetti, R. (2002). Transfection of pancreatic-derived beta-cells with a minigene encoding for human glucagon-like peptide-1 regulates glucose-dependent insulin synthesis and secretion. Endocrinology 143: 3529-3539.
16. Xu, L., et al. (2001). CMV-beta-actin promoter directs higher expression from an adeno-associated viral vector in the liver than the cytomegalovirus or elongation factor 1 alpha promoter and results in therapeutic levels of human factor X in mice. Hum. Gene Ther. 12: 563-573.
17. Kircheis, R., Wightman, L., and Wagner, E. (2001). Design and gene delivery activity of modified polyethylenimines. Adv. Drug Delivery Rev. 53: 341-358.
18. Godbey, W. T., Wu, K. K., and Mikos, A. G. (1999). Poly(ethylenimine) and its role in gene delivery. J. Controlled Release 60: 149-160.
19. Drucker, D. J. (2001). Minireview: the glucagon-like peptides. Endocrinology 142: 521-527.
20. Thorens, B., and Waeber, G. (1993). Glucagon-like peptide-1 and the control of insulin secretion in the normal state and in NIDDM. Diabetes, 42: 1219-1225.
21. Lacy, P. E., and Kostianovsky, M. (1967). Method for the isolation of intact islets of Langerhans from the rat pancreas. Diabetes 16: 35-39.